Art. -Nr.: HY-N0743

Senkyunolide A

Name: Senkyunolide A
Brand: MedChemExpress
SKU: HY-N0743
Price: 60.00 USD
Availability: InStock
Rating: 5 (4 reviews)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.06%
CAS. Nr.: 63038-10-8
Formel: C₁₂H₁₆O₂
Molecular Weight:192.26

Speicherung:

Shipping with dry ice

-80°C, protect from light, stored under nitrogen

Senkyunolide A Chemical Structure

CAS. Nr.: 63038-10-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[4]

α-synuclein

Alle α-synuclein Isoform-spezifische Produkte anzeigen :

In Vitro

Senkyunolide A (0-2.5 μg/mL; 24 h) inhibits the proliferation of HT-29 and CCD-18Co cells with IC₅₀ of 10.4 μM and 20.95 μM, respectively ^[1].
Senkyunolide A (100 μM; 6 h) inhibits the high expression of CD137 in TNF-α treated MAECs cells^[2].
Senkyunolide A (0.125-0.5 μg/mL; 24-72 h) improves cell viability, decreases apoptosis, LDH release, α-syn expression and PP2P phosphorylation in PC12 cells treated with corticosterone (HY-B1618)^[3].
Senkyunolide A (20-80 μg/mL; 48 h) promotes cell proliferation and inhibits cell apoptosis in IL-1β-treated chondrocytes, and inhibits cell inflammation by blocking the NLRP3 signaling pathway^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

Chondrocytes
Concentration:

20, 40 and 80 μg/mL
Incubation Time:

48 h
Result:

Decreased the levels of NLRP3, ASC and caspase-1.
Reduced the levels of TNF-a, IL-6 and IL-18.

Parmacokinetics

Species	Dose	Route	Note	T_1/2	Plasma Concentration	AUC	V_d	Clearance (CL)	T_max	Bioavailability
Rat^[5]	20 mg/kg	i.v.	pure	0.65 h	19.67 mg/L	2.81 mg·h/L	6.74 L/kg	7.20 L/h/kg	/	/
Rat^[5]	5.8 mg/kg	i.v.	ext	0.69 h	4.86 mg/L	0.95 mg/h/L	7.12 L/kg	9.17 L/h/kg	/	/
Rat^[5]	50 mg/kg	i.p.	/	0.67 h	17.6 mg/L	5.29 mg/h/L	9.98 L/kg	10.92 L/h/kg	0.04 h	75.3 %

In Vivo

Senkyunolide A (20-40 mg/kg; Intraperitoneal injection; 1 week) shows improvement in the mouse model of osteoarthritis^[4].
Pharmacokinetic Analysis in Rats^[5]

Route	Dose (mg/kg)	T_max (h)	C_max (mg/L)	t_1/2 (h)	AUC_0→∞ (mg/h per liter)	V_d/F (L/kg)	CL/F (L/h per kilogram)	F (%)
i.v.	20 (pure)	/	19.67	0.65	2.81	6.74	7.20	/
i.v.	7.65 (ext)*	/	4.86	0.69	0.95	7.12	9.17	/
i.p.	50	0.04	17.60	0.67	5.29	9.98	10.92	75.3
i.p.	100	0.04	31.01	0.99	10.65	13.78	9.72	75.8
p.o.	100	0.21	1.66	0.52	1.11	68.97	94.81	7.9

*The herbal extract containing 7.65% of senkyunolide A was given at a dose of 100 mg/kg.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 mice (200-220 g) with osteoarthritis^[4]
Dosage:

20 and 40 mg/kg
Administration:

Intraperitoneal injection (i.p.); 1 week
Result:

Alleviated articular cartilage destruction by inhibiting NLRP3 signalling pathway.
Significantly reduced the levels of NLRP3, ASC and caspase-1.

Related Protocols :

Chemical Information

CAS. Nr. 63038-10-8
Appearance Liquid (Density: 1.1±0.1 g/cm³)
Molecular Weight 192.26
Formel C₁₂H₁₆O₂
Color Colorless to light yellow
SMILES

O=C1O[C@@H](CCCC)C2=C1C=CCC2
Structure Classification
- Others
Initial Source
Versand

Shipping with dry ice.
Speicherung

-80°C, protect from light, stored under nitrogen

Publications (4)

All Cell Proliferation/Viability AssayWBIFApoptosis AnalysisHistological Imaging/Staining

Sort by:

Journal Impact Factor

Pharm Biol

Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway. [Abstract]

2022 Dec;60(1):535-542. PMID: 35225151

Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542. [Abstract]

The cell viability of chondrocytes treated with different concentrations of Senkyunolide A (SenA) (0, 20, 40, 80 and 160 μg/mL) was measured by MTT assay.

Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542. [Abstract]

Senkyunolide A (SenA) (20, 40, 80 μg/mL) inhibited the expression of catabolic marker proteins (MMP13, ADAMTS4/5) in IL-1β stimulated chondrocytes.

Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542. [Abstract]

Senkyunolide A (SenA) (20, 40, 80 μg/mL) promoted cell proliferation of IL-1b-stimulated chondrocytes.

Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542. [Abstract]

Senkyunolide A (SenA) (20, 40, 80 μg/mL) inhibited cell apoptosis of IL-1b-stimulated chondrocytes.

Senkyunolide A purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):535-542. [Abstract]

H&E staining was used to observe the pathological changes of knee joint treated with Senkyunolide A (SenA) (20, 40 mg/kg, i.p.).
Biochem Biophys Res Commun

Senkyunolide A alleviates asthma by inhibiting TGF-β/Smad2/3 signaling pathway and NLRP3 inflammasome activation. [Abstract]

2025 Nov 8:788:152809. PMID: 41129932
Biochem Biophys Res Commun

Senkyunolide A mitigates lipid deposition in hyperlipidemic hepatocytes through SIRT6-mediated suppression of oxidative stress and fetuin-A. [Abstract]

2025 Jul 22:771:152046. PMID: 40403679
Biomed Pharmacother

Guiqi Baizhu prescription ameliorates cytarabine-induced intestinal mucositis by targeting JAK2 to inhibit M1 macrophage polarization. [Abstract]

2023 Aug:164:114902. PMID: 37209628

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (520.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.2013 mL

26.0067 mL

52.0134 mL

5 mM

1.0403 mL

5.2013 mL

10.4027 mL

10 mM

0.5201 mL

2.6007 mL

5.2013 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (13.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (13.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (13.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kan WL, et al. Study of the anti-proliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells. J Ethnopharmacol. 2008 Oct 30;120(1):36-43. [Content Brief]

[2]. Lei W, et al. Phthalides, senkyunolide A and ligustilide, show immunomodulatory effect in improving atherosclerosis, through inhibiting AP-1 and NF-κB expression. Biomed Pharmacother. 2019 Sep;117:109074. [Content Brief]

[3]. Gong S, et al. Senkyunolide A protects neural cells against corticosterone-induced apoptosis by modulating protein phosphatase 2A and α-synuclein signaling. Drug Des Devel Ther. 2018 Jun 25;12:1865-1879. [Content Brief]

[4]. Shao M, et al. Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway. Pharm Biol. 2022 Dec;60(1):535-542. [Content Brief]

[5]. Yan R,et al. Low oral bioavailability and pharmacokinetics of senkyunolide a, a major bioactive component in Rhizoma Chuanxiong, in the rat. Ther Drug Monit. 2007 Feb;29(1):49-56. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.2013 mL	26.0067 mL	52.0134 mL	130.0336 mL
	5 mM	1.0403 mL	5.2013 mL	10.4027 mL	26.0067 mL
	10 mM	0.5201 mL	2.6007 mL	5.2013 mL	13.0034 mL
	15 mM	0.3468 mL	1.7338 mL	3.4676 mL	8.6689 mL
	20 mM	0.2601 mL	1.3003 mL	2.6007 mL	6.5017 mL
	25 mM	0.2081 mL	1.0403 mL	2.0805 mL	5.2013 mL
	30 mM	0.1734 mL	0.8669 mL	1.7338 mL	4.3345 mL
	40 mM	0.1300 mL	0.6502 mL	1.3003 mL	3.2508 mL
	50 mM	0.1040 mL	0.5201 mL	1.0403 mL	2.6007 mL
	60 mM	0.0867 mL	0.4334 mL	0.8669 mL	2.1672 mL
	80 mM	0.0650 mL	0.3251 mL	0.6502 mL	1.6254 mL
	100 mM	0.0520 mL	0.2601 mL	0.5201 mL	1.3003 mL

Bioz

Keywords

Senkyunolide A

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Senkyunolide A

Publications Citing Use of MedChemExpress (MCE) Senkyunolide A

Alle α-synuclein Isoform-spezifische Produkte anzeigen